Trial Profile
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Nivolumab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 602
- Sponsors Bristol-Myers Squibb
- 30 Nov 2023 This trial has been completed in Spain according to European Clinical Trials Database record.
- 28 Apr 2022 Status changed from active, no longer recruiting to completed.
- 05 Aug 2021 Planned End Date changed from 18 Mar 2021 to 16 Mar 2022.